General Information of Drug (ID: DM6AI9N)

Drug Name
AZD-2927 Drug Info
Synonyms AZD2927
Indication
Disease Entry ICD 11 Status REF
Atrial fibrillation BC81.3 Phase 2 [1]
Cross-matching ID
PubChem CID
57345449
TTD Drug ID
DM6AI9N

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug(s) Targeting Ion channel unspecific (IC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ATI-2042 DMWP59B Atrial fibrillation BC81.3 Phase 2 [2]
Lu-AA39959 DM34FWR Bipolar disorder 6A60 Phase 2 [3]
Lu-AA38466 DMGUX5Y Neurological disorder 6B60 Discontinued in Phase 1 [4]
AZD-0902 DMS7INR Chronic obstructive pulmonary disease CA22 Terminated [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ion channel unspecific (IC) TTM7WCE NOUNIPROTAC Modulator [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7704).
2 A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2012 Jun;34(1):1-9.
3 Lundbeck: leading the way in the treatment of CNS disorders.
4 Lundbeck is developing new and promising pharmaceuticals for the treatment of depression, anxiety and psychotic disorders and for new disease areas such as stroke and alcohol dependence. Pipeline report of Lundbeck in 2008.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019129)